SCHEMBL2891275

SCHEMBL2891275

Oc1ccc(/N=C/c2ccc(I)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.61
S100B P04271 3/20 0.61
ALDH1A1 P00352 6/20 0.59
MAPT P10636 5/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
L3MBTL1 Q9Y468 4/20 0.59
KDM4E B2RXH2 3/20 0.59
BLM P54132 3/20 0.59
ALOX15 P16050 3/20 0.59
HSD17B10 Q99714 3/20 0.59
TP53 P04637 2/20 0.59
MAPK1 P28482 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
LMNA P02545 2/20 0.59
POLB P06746 2/20 0.59
HSP90AA1 P07900 1/20 0.59
HSP90AB1 P08238 1/20 0.59
HPGD P15428 1/20 0.59
CA1 P00915 4/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2891277 1.00 CA2 (0.61) CA2S100BALDH1A1MAPTMEN1
SCHEMBL14373623 0.89 CA2 (0.71) CA2S100BALDH1A1MAPTMEN1
SCHEMBL11320970 0.89 CA2 (0.71) CA2S100BALDH1A1MAPTMEN1
SCHEMBL15347676 0.89 CA2 (0.71) CA2S100BALDH1A1MAPTMEN1
SCHEMBL2839684 0.89 CA2 (0.71) CA2S100BALDH1A1MAPTMEN1
SCHEMBL11450591 0.80 CA2 (0.61) CA2S100BALDH1A1MAPTMEN1
SCHEMBL10045762 0.80 CA2 (0.61) CA2S100BALDH1A1MAPTMEN1
SCHEMBL11458614 0.80 S100B (0.66) CA2S100BALDH1A1MAPTMEN1
SCHEMBL11458615 0.80 S100B (0.66) CA2S100BALDH1A1MAPTMEN1
SCHEMBL1033699 0.80 CA2 (0.61) CA2S100BALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069347-A1 HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS MERCK SHARP & DOHME CORP. 2010-03-18 US disclosed
US-20100069347-A1 HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS MERCK SHARP & DOHME CORP. 2010-03-18 US disclosed
US-20100069347-A1 HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS MERCK SHARP & DOHME CORP. 2010-03-18 US disclosed
WO-2008057336-A2 HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS MERCK & CO., INC. (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069347-A1 HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS LDLR, PCSK9, CYP46A1 CA2 3492/4885S100B 4605/4885ALDH1A1 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.